textabstractReference pricing and health technology assessment are policies commonly applied in order to obtain more value for money from pharmaceuticals. This study focussed on decisions about the initial price and reimbursement status of innovative drugs and discussed the consequences for market access and cost. Four countries were studied: Germany, The Netherlands, Sweden and the United Kingdom. These countries have operated one, or both, of the two policies at certain points in time, sometimes in parallel. Drugs in four groups were considered: cholesterol-lowering agents, insulin analogues, biologic drugs for rheumatoid arthritis and "atypical" drugs for schizophrenia. Compared with HTA, reference pricing is a relatively blunt instrumen...
With the rising costs of health care due to an ageing population and a growing number of new and exp...
Recently, the need for health care services has increased gradually and the limitations in sources a...
Artículo de publicación SciELOThe article conceptualizes the pharmaceutical pricing and reimbursemen...
Reference pricing and health technology assessment are policies commonly applied in order to obtain ...
Pharmaceuticals, Reimbursement, Cost-effectiveness analysis, Health policy, I10, I18,
Introduction: Drug reimbursement decisions are often made based on a price set by the manufacturer. ...
Introduction: Drug reimbursement decisions are often made based on a price set by the manufacturer. ...
Introduction Drug reimbursement decisions are often made based on a price set by the manufacturer. I...
Since the late 1970s, many European countries have established health technology assessment (HTA) sy...
The pharmaceutical policy environment is dynamic as new medicines are being developed and different ...
This paper describes three prototypical systems of therapeutic reference pricing (RI') for phar...
This paper reviews the literature on reference pricing (RP) in pharmaceutical markets. The RP strate...
Sorenson Since the late 1970s, many European coun-tries have established health technology assessmen...
Prescription drugs are major components of health care costs. Given rising pharmaceutical expenditur...
This thesis investigated whether medicines could be used more quickly by patients through better coo...
With the rising costs of health care due to an ageing population and a growing number of new and exp...
Recently, the need for health care services has increased gradually and the limitations in sources a...
Artículo de publicación SciELOThe article conceptualizes the pharmaceutical pricing and reimbursemen...
Reference pricing and health technology assessment are policies commonly applied in order to obtain ...
Pharmaceuticals, Reimbursement, Cost-effectiveness analysis, Health policy, I10, I18,
Introduction: Drug reimbursement decisions are often made based on a price set by the manufacturer. ...
Introduction: Drug reimbursement decisions are often made based on a price set by the manufacturer. ...
Introduction Drug reimbursement decisions are often made based on a price set by the manufacturer. I...
Since the late 1970s, many European countries have established health technology assessment (HTA) sy...
The pharmaceutical policy environment is dynamic as new medicines are being developed and different ...
This paper describes three prototypical systems of therapeutic reference pricing (RI') for phar...
This paper reviews the literature on reference pricing (RP) in pharmaceutical markets. The RP strate...
Sorenson Since the late 1970s, many European coun-tries have established health technology assessmen...
Prescription drugs are major components of health care costs. Given rising pharmaceutical expenditur...
This thesis investigated whether medicines could be used more quickly by patients through better coo...
With the rising costs of health care due to an ageing population and a growing number of new and exp...
Recently, the need for health care services has increased gradually and the limitations in sources a...
Artículo de publicación SciELOThe article conceptualizes the pharmaceutical pricing and reimbursemen...